Skip to content
← All settings

DISEASE & TREATMENT SETTING

VOTRIENT: advanced Soft tissue sarcoma after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1.2 Soft Tissue Sarcoma VOTRIENT is indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.

Broader topic: Soft Tissue Sarcoma

Source population
Not part of this definition
Disease extent
advanced
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      who have received prior chemotherapy
      status
      required
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for VOTRIENT (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    1.2 Soft Tissue Sarcoma VOTRIENT is indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.

    Study evidence for this setting

    0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice